Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

GE to Expand in Biomedical and Life Sciences with Strategic Acquisitions from Thermo Fisher Scientific

By BiotechDaily International staff writers
Posted on 15 Jan 2014
General Electric (GE; Fairfield, CT, USA) and Thermo Fisher Scientific (Waltham, MA, USA) have entered into an agreement for GE’s subsidiary GE Healthcare (Little Chalfont, UK) to acquire cell culture media and sera, gene modulation, and magnetic beads businesses from Thermo Fisher for approximately USD 1.06 billion. The three businesses to be acquired generated combined annual revenues of approximately USD 250 million in 2013.

GE Healthcare’s leadership in medical diagnostic technology includes its USD 4 billion life sciences business. The acquisition, anticipated to close in early 2014 (subject to regulatory approvals), will allow GE to expand its offering and development of technologies for the discovery and manufacturing of innovative new medicines, cell therapies, vaccines, and diagnostics in the biomedical sector of its growing life sciences division. It will also extend GE’s bioprocessing manufacturing footprint in Asia, the Americas, and Europe.

Thermo Fisher’s HyClone cell culture media and sera products are highly complementary to GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, enabling GE to offer its customers a substantially wider range of technologies and services. Thermo Fisher’s gene modulation technologies complement GE’s established technologies for drug discovery research, and the Sera-Mag magnetic beads product line extends GE’s existing technologies in protein analysis and medical diagnostics. The complementary product offerings and strong strategic fit of the acquisitions will also enable GE Healthcare to expand and accelerate the development of new “end-to-end” technologies.

“Life sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines. Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research, and patients. This deal [...] will help us realize our vision of bringing better healthcare to more people at lower cost,” said John Dineen, president and CEO, GE Healthcare.

“We look forward to the HyClone cell culture and other businesses joining the GE family. They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business,” said Kieran Murphy, president and CEO of GE Healthcare’s life sciences division. “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing. They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera.”

Related Links:
General Electric
GE Healthcare
Thermo Fisher Scientific


Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.